Introduction {#s1}
============

Fate mapping studies in vivo show there are multiple distinct waves of mesenchymal progenitors that form skeletal tissues during development and then maintain the skeleton throughout adulthood ([@bib36]; [@bib39]; [@bib44]; [@bib60]; [@bib67]; [@bib71]; [@bib75]). These include Osterix^+^ cells that give rise to osteoblasts, osteocytes, and stromal cells in developing bones ([@bib36]; [@bib39]; [@bib44]), Nestin-CreER-expressing cells that transiently form osteoblasts and bone marrow stromal cells in the early postnatal period ([@bib48]; [@bib56]; [@bib67]), *Grem1*-expressing cells that form osteoblasts, chondrocytes, and stromal cells postnatally ([@bib71]) and Leptin Receptor (LepR)-expressing stromal cells that are the major source of bone and adipocytes in adult mouse bone marrow ([@bib44]; [@bib75]). Osterix^+^ osteogenic progenitors also persist periosteally, on the outer surface of adult bones, where they help to repair bone injuries ([@bib39]).

Bone marrow stromal cells include skeletal stem cells (SSCs) as well as multiple other populations of mesenchymal progenitors ([@bib10]). SSCs are multipotent progenitors that form fibroblast colonies in culture (CFU-F) with the potential to differentiate into osteoblasts, chondrocytes, and adipocytes ([@bib6]; [@bib15]). Bone marrow CFU-F can be identified based on the expression of CD146, CD271, VCAM-1, and Thy-1 in humans, or LepR, PDGFRα, CD51, and/or CD105 in mice, as well as the lack of expression of hematopoietic and endothelial markers ([@bib9], [@bib10]; [@bib24]; [@bib38]; [@bib46]; [@bib55]; [@bib60]; [@bib64]; [@bib75]). CFU-F are enriched among bone marrow stromal cells that express high levels of the hematopoietic growth factors *Scf* ([@bib75]) and *Cxcl12* ([@bib12]; [@bib54]; [@bib65]).

Multiple growth factor families promote osteogenesis including Wnts ([@bib11]; [@bib32]), Bone Morphogenetic Proteins (BMPs) ([@bib49]; [@bib61]), and Insulin-like Growth Factors ([@bib72]). However, these factors have broad effects on many tissues, precluding their systemic administration to promote osteogenesis. Sclerostin, a Wnt signaling inhibitor that is locally produced by osteocytes, negatively regulates bone formation ([@bib34]). Sclerostin inhibitors can be administered systemically to promote bone formation ([@bib40]). Factors secreted by bone marrow stromal cells promote osteogenesis ([@bib10]), though the full repertoire of such factors remains to be identified.

Osteoporosis is a progressive bone disease characterized by decreased bone mass and increased fracture risk ([@bib17]). Aging, estrogen insufficiency, long-term glucocorticoid use, and mechanical unloading all contribute to the development of osteoporosis ([@bib17]). Most existing osteoporosis therapies involve antiresorptive agents, such as bisphosphonates ([@bib7]; [@bib35]) and estrogens ([@bib42]), which reduce the rate of bone loss but do not promote new bone formation. Teriparatide, a small peptide derived from human parathyroid hormone (PTH; amino acids 1--34) is used clinically to promote the formation of new bone ([@bib51]). Nonetheless, some patients cannot take Teriparatide ([@bib31]) and its use is limited to two years because of a potential risk of osteosarcoma ([@bib51]).

Clec11a (C-type lectin domain family 11, member A) is a secreted sulfated glycoprotein that is expressed in the bone marrow and can promote colony formation by human hematopoietic progenitors in culture ([@bib4], [@bib3]; [@bib20]; [@bib43]). The plasma level of human Clec11a correlates with hemoglobin level ([@bib27]; [@bib58]) and increases in patients after bone marrow transplantation ([@bib23]). As a result, Clec11a has been considered a hematopoietic growth factor. However, *Clec11* is also expressed in skeletal tissues ([@bib21]) and the physiological function of Clec11a in vivo has not yet been tested.

Results {#s2}
=======

*Clec11a* is expressed by subsets of bone marrow stromal cells, osteoblasts, osteocytes and hypertrophic chondrocytes {#s2-1}
---------------------------------------------------------------------------------------------------------------------

Reanalysis of our published microarray data ([@bib13]) revealed that among enzymatically dissociated bone marrow cells, *Clec11a* was significantly more highly expressed by *Scf-*GFP^+^CD45^-^Ter119^-^CD31^-^ stromal cells (more than 90% of which are also LepR^+ ^\[[@bib75]\]) and Col2.3-GFP^+^CD45^-^Ter119^-^CD31^-^ osteoblasts as compared to VE-cadherin^+^ endothelial cells and unfractionated cells ([Figure 1A](#fig1){ref-type="fig"}). By RNA sequencing, *Clec11a* transcripts were at least 100-fold more abundant in PDGFRα^+^CD45^-^Ter119^-^CD31^-^ bone marrow stromal cells (more than 90% of which are LepR^+ ^\[[@bib75]\]) as compared to unfractionated bone marrow cells ([Figure 1B](#fig1){ref-type="fig"}). A systematic analysis of *Clec11a* expression in bone marrow cells by quantitative reverse transcription PCR (qRT-PCR) showed that *Clec11a* was highly expressed by LepR^+^CD45^-^Ter119^-^CD31^-^ stromal cells and Col2.3-GFP^+^CD45^-^Ter119^-^CD31^-^ osteoblasts but not by hematopoietic cells ([Figure 1C](#fig1){ref-type="fig"}). *Clec11a* was also expressed at a very low level by B cell progenitors in the bone marrow and T cells in the spleen ([Figure 1C](#fig1){ref-type="fig"}).10.7554/eLife.18782.002Figure 1.*Clec11a* deficient mice were grossly developmentally normal and had normal hematopoiesis.(**A--C**) *Clec11a* expression analysis by microarray, RNA-seq and qRT-PCR. Whole bone marrow cells, VE-Cadherin^+^ bone marrow endothelial cells, bone marrow stromal cells (*Scf*-GFP^+^CD45^-^Ter119^-^CD31^-^ for microarray, PDGFRα^+^CD45^-^Ter119^-^CD31^-^ for RNA-seq, and LepR^+^CD45^-^Ter119^-^CD31^-^ for qPCR), *Col2.3*-GFP^+^CD45^-^Ter119^-^CD31^-^ osteoblasts and hematopoietic cell populations were sorted from enzymatically dissociated femur bone marrow of two month-old mice, followed by microarray (**A**), RNA-seq (**B**) and qPCR (**C**) analysis. The statistical significance of differences was assessed using one-way ANOVAs with Dunnett's multiple comparison tests (n = 2--3 mice/genotype from at least two independent experiments). (**D**) The position of images from femur sections. (**E--H**) Confocal analysis of isotype control or anti-Clec11a antibody staining in the femur metaphysis (**E** and **F**) and diaphysis (**G** and **H**) of *Prrx1-Cre; tdTomato* mice. Bone was imaged by second harmonic generation (SHG). Bone marrow stromal cells (**Fi**), osteoblasts (**Fii**), hypertrophic chondrocytes (**Fiii**) and osteocytes (**H**) are marked by arrows (n = 3 mice per genotype, total, from three independent experiments). (**I** and **J**) Confocal analysis of isotype control (**I**) or anti-Clec11a antibody staining (**J**) in the femur metaphysis of *Lepr-Cre; tdTomato* mice. LepR^+^ bone marrow stromal cells are marked by arrows (n = 3 mice per genotype, total, from three independent experiments). (**K**) Representative images of two month-old control and *Clec11a^-/-^* mice. (**L**) Body mass of 2 and 10 month-old mice (n = 3--8 mice per genotype, total, from at least three independent experiments for all data in panels **L--T**). (**M**) Cellularity of the bone marrow and spleen. (**N--T**) Flow cytometric analysis of the frequencies of myeloid cells (**N**), erythroid progenitors (**O**), T cells (**P**), B cells (**Q**), hematopoietic stem cells (**R**), multipotent progenitors (**S**) and restricted progenitors (**T**) in the bone marrow and spleen of *Clec11a^-/-^* mice and sex-matched littermate controls. The statistical significance of differences among genotypes was assessed using two-tailed Student's t tests. Data represent mean ± SD: \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. The source data are in [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.002](10.7554/eLife.18782.002)10.7554/eLife.18782.003Figure 1---source data 1.Data for [Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.003](10.7554/eLife.18782.003)10.7554/eLife.18782.004Figure 1---figure supplement 1.Generation of *Clec11a^-/-^* mice and hematopoietic analysis.(**A** and **B**) Anti-Clec11a antibody staining (green) of distant femur metaphysis (**A**) and diaphysis cortical bone (**B**) sections from *Clec11a^-/-^* mice and wild-type controls. (**C**) Anti-Clec11a antibody staining (green) of sections through vertebral trabecular and cortical bone in wild-type mice. (**D**) Anti-Clec11a antibody staining (green) of distant femur metaphysis in *Prrx1-Cre; tdTomato* mice. Growth plate chondrocytes were marked by aggrecan staining. Bone was imaged by second harmonic generation (SHG). (**E** and **F**) Targeting strategy to generate a loss-of-function *Clec11a* allele using Crispr-Cas9 gene targeting. Two sgRNAs were designed against sequences in intron 1 and intron 2 (arrowheads) to engineer the deletion of exon 2 (**E**), which caused a frame shift that created a premature stop codon in exon 3 (**F**). The resulting mutant protein has 76 amino acids, lacking all of the domains that are thought to be functionally important in Clec11a (**F**). Genotyping (black arrows) and qPCR (red arrows) primer locations are marked in (**E**). (**G**) Genomic DNA PCR. Tail genomic DNA was extracted from *Clec11a^+/+^* and *Clec11a^-/-^* mice, followed by PCR amplification using the primers indicated in (**E**) with black arrows. The amplicons were sequenced to confirm correct targeting. (**H**) qPCR analysis of *Clec11a* expression in sorted LepR^+^CD45^-^Ter119^-^CD31^-^ cells from *Clec11a^+/+^* and *Clec11a^-/-^* bone marrow using the primers marked in panel **E** (red arrows). Statistical significance was assessed using a two-tailed Student's t test (n = 5 mice per genotype, total, from three independent experiments). (**I**) *Clec11a* cDNA was amplified by RT-PCR from bone marrow stromal cells using primers located in exon 1 and exon 3 (black arrows) and subjected to Sanger sequencing. Deletion of exon 2 in *Clec11a^-/-^* mice led to an aberrant transcript that joined exon 1 and exon 3, causing a frame shift and formation of a premature stop codon in exon 3 (see panel **F**). (**J**) ELISA measurement of plasma Clec11a level in 2 month-old *Clec11a^+/+^*, *Clec11a^+/-^* and *Clec11a^-/-^* mice (n = 3--6 mice per genotype, total, from three independent experiments). (**K**) Heterozygous *Clec11a^+/-^* mice were intercrossed and generated progeny in Mendelian ratios (p=0.37 relative to expected numbers by Chi-square test). (**L--N**) Red blood cell (**L**), white blood cell (**M**) and platelet (**N**) counts in 2, 10 and 16 month-old *Clec11a^-l-^* and sex-matched littermate control mice (n = 4--6 mice per genotype, total, from at least four independent experiments). The statistical significance of differences among genotypes was assessed using two-tailed Student's t tests. (**O--R**) Competitive reconstitution analysis of irradiated mice transplanted with 300,000 donor bone marrow cells from *Clec11a^-/-^* or littermate control mice along with 300,000 recipient bone marrow cells. All mice were long-term multilineage reconstituted by donor cells (**O**), including CD3^+^ T cells (**P**), B220^+^ B cells (**Q**) and Mac1^+^Gr-1^+^ myeloid cells (**R**) (n = 10 recipients per genotype, total, from two independent experiments). The statistical significance of differences among genotypes was assessed using repeated measures two-way ANOVAs with Sidak's multiple comparison tests. (**S** and **T**) Hematopoietic colony formation by mouse bone marrow cells in cultures supplemented with rClec11a along with 1 U/ml EPO to promote erythroid progenitor colony formation (BRU-E; **S**) or 10 ng/ml GM-CSF to promote myeloid progenitor colony formation (CFU-G/M/GM; **T**) (n = 3 independent experiments). The statistical significance of differences among treatments was assessed using one-way ANOVAs with Tukey's multiple comparison tests. The data represent mean ± SD (\*p\<0.05, \*\*\*p\<0.001) from male and female mice. The source data are in [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.004](10.7554/eLife.18782.004)

Published gene expression profile data were consistent with our results. RNA-seq analysis showed 80-fold higher levels of *Clec11a* in bone fragments that contain osteoblasts and osteocytes as compared to whole bone marrow or skeletal muscle cells ([@bib2]). *Clec11a* expression is 9-fold higher in Grem1^+^ SSCs as compared to Grem1^-^ stromal cells (see GSE57729 from \[[@bib71]\]). LepR^+^ stromal cells are enriched for *Grem1* expression (see GSE33158 from \[[@bib13]\]).

To assess the Clec11a protein expression, we stained femur sections from eight week-old *Prrx1-Cre; tdTomato* reporter mice with a commercial polyclonal antibody against Clec11a. *Prrx1-Cre* recombines in limb bone marrow mesenchymal cells including SSCs, other bone marrow stromal cells, osteoblasts, osteocytes, and chondrocytes ([@bib12]; [@bib16]; [@bib37]; [@bib74]). In two month-old mice, most of the Clec11a staining was observed in and around the trabecular bone in the femur metaphysis ([Figure 1F](#fig1){ref-type="fig"}) as well as in cortical bone of the proximal femur ([Figure 1H](#fig1){ref-type="fig"}). This staining pattern was specific for Clec11a as we did not observe any staining in bone marrow sections from *Clec11a* deficient mice ([Figure 1---figure supplement 1A and B](#fig1s1){ref-type="fig"}; see below) or in sections stained with an isotype control in place of the anti-Clec11a antibody ([Figure 1E,G, and I](#fig1){ref-type="fig"}).

Within the distal femur metaphysis of *Prrx1-Cre; tdTomato* mice we observed Clec11a staining adjacent to Tomato^+^ stromal cells in the bone marrow near trabecular bone ([Figure 1Fi](#fig1){ref-type="fig"}), Tomato^+^ osteoblasts lining trabecular bone surfaces ([Figure 1Fii](#fig1){ref-type="fig"}), and Aggrecan^+^ hypertrophic chondrocytes ([Figure 1Fiii](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). In the cortical bone matrix, we also observed Clec11a staining amongst osteocytes ([Figure 1H](#fig1){ref-type="fig"}). We did not detect Clec11a expression by bone marrow stromal cells, osteoblasts, or osteocytes in much of the diaphysis. Nonetheless, given the tendency of secreted growth factors to concentrate in regions of extracellular matrix, especially within the bone matrix ([@bib19][@bib18]; [@bib45]), Clec11a may be more broadly expressed by bone marrow stromal cells than is evident from the antibody staining pattern.

The position and morphology of the metaphyseal bone marrow stromal cells that were associated with Clec11a staining ([Figure 1Fi](#fig1){ref-type="fig"}) suggested that these cells included LepR^+^ cells. To test this, we stained femur sections from eight week-old *Lepr-Cre; tdTomato* mice with anti-Clec11a antibody. We observed Clec11a staining adjacent to a subset of Tomato^+^ stromal cells near trabecular bone in the metaphysis ([Figure 1J](#fig1){ref-type="fig"}) but not by Tomato^+^ stromal cells throughout most of the diaphysis. The Clec11a staining in LepR^+^ cells in the metaphysis ([Figure 1J](#fig1){ref-type="fig"}) was clearly above background ([Figure 1I](#fig1){ref-type="fig"}) but was dimmer than observed in and around bone matrix ([Figure 1F and H](#fig1){ref-type="fig"}). It is unclear whether this reflects the lower Clec11a expression by the LepR^+^ cells or whether Clec11a is bound and concentrated by bone matrix.

We observed a similar Clec11a expression pattern in vertebrae, with anti-Clec11a antibody staining in and around the vertebral trabecular bone near the growth plate as well as in cortical bone ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Our data thus indicate that Clec11a is expressed by subsets of LepR^+^ bone marrow stromal cells, osteoblasts, and hypertrophic chondrocytes in the metaphysis as well as by osteocytes in certain regions of cortical bone.

*Clecl11a* is not required for hematopoiesis in normal mice {#s2-2}
-----------------------------------------------------------

To test the physiological function of *Clec11a* we used CRISPR-Cas9 to generate a *Clec11a* mutant allele (*Clec11a^-/-^*) by deleting the second exon of *Clec11a* ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). This was predicted to be a strong loss of function as exon 2 deletion introduced a frame shift that created a premature stop codon in exon 3 ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}). The predicted mutant protein did not contain any of the domains that are thought to be functionally important in Clec11a, including the polyglutamic acid sequence, the alpha-helical leucine zipper, or the C-type lectin domain ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}). Germline transmission of the mutant allele was confirmed by PCR and sequencing of genomic DNA ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}). *Clec11a* deficiency was also confirmed by qPCR analysis of bone marrow LepR^+^CD45^-^Ter119^-^CD31^-^ cells from *Clec11a^-/-^* mice ([Figure 1---figure supplement 1H](#fig1s1){ref-type="fig"}) and by *Clec11a* cDNA sequencing to confirm exon two deletion ([Figure 1---figure supplement 1I](#fig1s1){ref-type="fig"}), and by the loss of Clec11a from the plasma *Clec11a^-/-^* mice ([Figure 1---figure supplement 1J](#fig1s1){ref-type="fig"}). Immunofluorescence analysis of femur sections with an anti-Clec11a polyclonal antibody suggested a complete loss of Clec11a protein from *Clec11a^-/-^* mice ([Figure 1---figure supplement 1A and B](#fig1s1){ref-type="fig"}).

*Clec11a^-/-^* mice were born with Mendelian frequency ([Figure 1---figure supplement 1K](#fig1s1){ref-type="fig"}) and appeared grossly normal ([Figure 1K](#fig1){ref-type="fig"}), with normal body mass at 2 and 10 months of age ([Figure 1L](#fig1){ref-type="fig"}). White blood cell, red blood cell, and platelet counts were normal in 2, 10, and 16 month-old *Clec11a^-/-^* mice ([Figure 1---figure supplement 1L--N](#fig1s1){ref-type="fig"}). Two and 10-month old *Clec11a^-/-^* mice also had normal bone marrow and spleen cellularity ([Figure 1M](#fig1){ref-type="fig"}), as well as normal frequencies of Mac1^+^Gr1^+^ myeloid cells, Ter119^+^CD71^+^ erythroid progenitors, CD3^+^ T cells, and B220^+^ B cells in the bone marrow and spleen ([Figure 1N--Q](#fig1){ref-type="fig"}). *Clec11a^-/-^* mice had normal frequencies of CD150^+^CD48^-^Lineage^-^Sca-1^+^c-kit^+^ HSCs ([@bib28]) and CD150^-^CD48^-^Lin^-^Sca-1^+^c-kit^+^multipotent progenitors (MPPs) ([@bib29]; [@bib53]) in the bone marrow and spleen ([Figure 1R and S](#fig1){ref-type="fig"}), as well as normal frequencies of CD34^+^FcγR^+^Lin^-^Sca-1^-^c-kit^+^granulocyte-macrophage progenitors (GMPs), CD34^-^FcγR^-^Lin^-^Sca-1^-^c-kit^+^megakaryocyte-erythrocyte progenitors (MEPs), CD34^+^FcγR^-^Lin^-^Sca-1^-^c-kit^+^ common myeloid progenitors (CMPs) ([@bib1]) and Flt3^+^IL7Rα^+^Lin^-^Sca-1^low^c-kit^low^common lymphoid progenitors (CLPs) ([@bib30]) in the bone marrow ([Figure 1T](#fig1){ref-type="fig"}). Bone marrow from two month-old *Clec11a^-/-^* mice gave long-term multilineage reconstitution upon transplantation into irradiated mice with normal levels of donor cell reconstitution ([Figure 1---figure supplement 1O--R](#fig1s1){ref-type="fig"}). *Clec11a* is therefore not required for normal hematopoiesis in adult mice.

Human recombinant Clec11a increases erythroid (BFU-E) and myeloid (CFU-G/M/GM) colony formation by human bone marrow cells when added to culture along with EPO or GM-CSF, respectively ([@bib20][@bib21]). In cultures of mouse bone marrow cells, recombinant mouse Clec11a did not significantly increase BFU-E colony formation when added along with EPO and only slightly increased CFU-G/M/GM colony formation when added along with GM-CSF ([Figure 1---figure supplement 1S and T](#fig1s1){ref-type="fig"}).

*Clec11a* is required for normal levels of osteogenesis in vivo {#s2-3}
---------------------------------------------------------------

To test whether Clec11a regulates osteogenesis we performed micro-CT analysis of the distal femur from sex-matched littermates. In no case did we observe any significant difference between *Clec11a^+/+^* and *Clec11a^+/-^* mice (data not shown), so samples from these mice were combined as controls. We always compared sex-matched littermates within individual experiments, using paired statistical tests to assess the significance of differences across multiple independent experiments. Trabecular bone volume was significantly reduced (by 24 ± 18%) in two month-old *Clec11a^-/-^* mice as compared to littermate controls ([Figure 2A and D](#fig2){ref-type="fig"}). The *Clec11a^-/-^* mice had significantly reduced trabecular bone thickness, increased trabecular spacing, and decreased connectively density and bone mineral density ([Figure 2D--I](#fig2){ref-type="fig"}). With the exception of the reduction in bone mineral density, these defects seemed to worsen with age as 10 and 16 month-old *Clec11a^-/-^* mice exhibited more profound reductions in trabecular bone volume (62 ± 27% and 64 ± 11%, respectively), trabecular number, trabecular thickness and connectivity density, as well as increased trabecular spacing ([Figure 2B--H](#fig2){ref-type="fig"}).10.7554/eLife.18782.005Figure 2.Clec11a is necessary for osteogenesis in limb bones and vertebrae.(**A--C**) MicroCT images of trabecular bone in the distal femur metaphysis of two month-old (**A**), 10 month-old (**B**) and 16 month-old (**C**) *Clec11a^-/-^* mice and sex-matched littermate controls. (**D--I**) MicroCT analysis of trabecular bone volume/total volume (**D**), trabecular number (**E**), trabecular thickness (**F**), trabecular spacing (**G**), connectivity density (**H**) and bone mineral density (**I**)) in the distal femur metaphysis of 2, 10 and 16 month-old *Clec11a^-/-^* mice and sex-matched littermate controls (n = 4--9 mice/genotype from at least four independent experiments). (**J--L**) MicroCT images of trabecular bone from the ventral L3 lumbar vertebrae of two month-old (**J**), 10 month-old (**K**) and 16 month-old (**L**) *Clec11a^-/-^* mice and sex-matched littermate controls. (**M--R**) MicroCT analysis of trabecular bone parameters in the L3 vertebral bodies of 2, 10 and 16 month-old *Clec11a^-/-^* mice and sex-matched littermate controls (n = 3--5 mice per genotype, total, from at least three independent experiments). (**S--U**) Representative calcein double labeling images (**S**) with quantification of the trabecular bone mineral apposition (**T**) and trabecular bone formation (**U**) rates in the femur metaphysis of 2 and 10 month-old mice (n = 4 mice per genotype, total, from four independent experiments). (**V**) Bone resorption analysis by measuring the deoxypyridinoline/creatinine ratio in urine (n = 4 mice/genotype from four independent experiments). The statistical significance of differences among genotypes was assessed using two-tailed Student's paired t tests. Data represent mean ± SD (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001). All means included data from male and female mice but within individual experiments sex-matched littermates were compared by paired tests. The source data are in [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.005](10.7554/eLife.18782.005)10.7554/eLife.18782.006Figure 2---source data 1.Data for [Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.006](10.7554/eLife.18782.006)10.7554/eLife.18782.007Figure 2---figure supplement 1.Further skeleton analysis in *Clec11a^-/-^* mice.(**A--C**) Representative microCT images of cortical bone in the femur diaphysis of two month-old (**A**), 10 month-old (**B**) and 16 month-old (**C**) *Clec11a^-/-^* mice and sex-matched littermate controls. (**D--H**) MicroCT analysis of the total area (**D**), cortical area (**E**), cortical area/total area (**F**), cortical thickness (**G**) and cortical bone mineral density (**H**) in the femur diaphysis (n = 4--9 mice per genotype, total, from at least four independent experiments). (**I**) Femur length (n = 4--8 mice per genotype, total, from at least four independent experiments). (**J--L**) Biomechanical tests of the peak load (**J**), fracture energy (**K**), and yield load (**L**) in the femur diaphysis (n = 4--9 mice per genotype, total, from at least four independent experiments). (**M--R**) MicroCT analysis of the whole L3 lumbar vertebrae in 2, 10 and 16 month-old *Clec11a^-/-^* mice and sex-matched littermate controls (n = 3--5 mice per genotype, total, from at least three independent experiments). (**S**) Alizarin red/alcian blue double staining of a *Clec11a^-/-^* mouse and a littermate control at postnatal day 3 (images are representative of 3--4 mice per genotype, analyzed in two independent experiments). (**T** and **U**) CFU-F frequency (**T**) and cells per CUF-F colony (**U**) in 2 and 10 month-old mice (n = 6 mice per genotype, total, from six independent experiments). The statistical significance of differences was assessed using two-tailed Student's t tests. Data represent mean ± SD (\*p\<0.05, \*\*p\<0.01 and \*\*\*p\<0.001). All means included data from male and female mice but within individual experiments sex-matched littermates were compared using pairwise analyses. The source data are in [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.007](10.7554/eLife.18782.007)

MicroCT analysis of cortical bone parameters in the femur diaphysis from sex-matched littermates did not show significant differences between *Clec11a^-/-^* and control mice at 2 or 10 months of age ([Figure 2---figure supplement 1A and B](#fig2s1){ref-type="fig"}). However, 16 month-old *Clec11a^-/-^* mice exhibited significantly reduced cortical bone area, cortical area/total area ratio, and cortical thickness as compared to controls ([Figure 2---figure supplement 1C--H](#fig2s1){ref-type="fig"}). The femur length was slightly but significantly reduced in 2, 10 and 16 month-old *Clec11a^-/-^* mice as compared to littermate controls ([Figure 2---figure supplement 1I](#fig2s1){ref-type="fig"}). When we tested the mechanical strength of bones using a three point bending test we found significantly reduced peak load and fracture energy in the femur diaphysis of 2, 10, and 16 month-old *Clec11a^-/-^* as compared to sex-matched littermate control mice ([Figure 2---figure supplement 1J--L](#fig2s1){ref-type="fig"}).

Micro-CT analysis of L3 vertebrae as a whole, including both cortical and trabecular bone, showed a trend toward reduced bone volume in *Clec11a^-/-^* as compared to sex-matched littermate controls, though the difference was not statistically significant ([Figure 2---figure supplement 1M--R](#fig2s1){ref-type="fig"}). Trabecular bone volume was significantly reduced in the L3 vertebral body of *Clec11a^-/-^* as compared to controls at 2, 10, and 16 months of age ([Figure 2J--M](#fig2){ref-type="fig"}). We also observed significantly reduced trabecular number and significantly increased trabecular spacing in L3 vertebrae from 2, 10 and 16 month-old *Clec11a^-/-^* as compared to littermate controls ([Figure 2N--P](#fig2){ref-type="fig"}). Clec11a is therefore required to maintain limb and vertebral bone.

Alizarin red/alcian blue double staining at postnatal day 3 did not reveal any significant differences between *Clec11a*^-/-^ and littermate control mice ([Figure 2---figure supplement 1S](#fig2s1){ref-type="fig"}). This suggests that Clec11a is not required for fetal skeletal development.

We performed calcein double labeling to assess the rate of trabecular bone formation ([Figure 2S](#fig2){ref-type="fig"}). The trabecular bone mineral apposition and trabecular bone formation rates were both significantly decreased in the femur metaphysis of 2 and 10 month-old *Clec11a^-/-^* as compared to sex-matched littermate control mice ([Figure 2T](#fig2){ref-type="fig"} and U; 16 month-old mice were not assessed in these experiments). In contrast, the urinary bone resorption marker deoxypyridinoline did not significantly differ between *Clec11a^-/-^* and littermate controls ([Figure 2V](#fig2){ref-type="fig"}). This suggests that the difference in trabecular bone volume between *Clec11a^-/-^* and littermate control mice reflected reduced bone formation, not a change in bone resorption.

Clec11a is necessary for mesenchymal progenitor differentiation into mature osteoblasts {#s2-4}
---------------------------------------------------------------------------------------

To assess the mechanism by which Clec11a promotes osteogenesis in vivo we used multiple approaches to test whether it regulates the maintenance, proliferation, or differentiation of mesenchymal progenitors in the bone marrow. The frequency of LepR^+^CD45^-^Ter119^-^Tie2^-^ stromal cells did not significantly differ between the bone marrow of *Clec11a^-/-^* and littermate control mice ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). We also did not detect any difference in the rate of BrdU incorporation by these cells in vivo ([Figure 3---figure supplement 1H](#fig3s1){ref-type="fig"}) or the percentage of these cells that stained positively for activated caspase 3/7 (data not shown).

We also examined a series of mesenchymal stem and progenitor cell populations that had been identified in a prior study of postnatal day 3 bone marrow based on expression of CD51 and other markers ([@bib10]). In 10 month-old bone marrow we were able to identify 5 of the 8 cell populations that had been identified in the neonatal bone marrow ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). All of these cell populations were uniformly or nearly uniformly positive for LeprR expression as nearly all CD51^+^ bone marrow stromal cells were LepR^+^ and vice versa ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Consistent with the data on LepR^+^ cells above, we did not detect any effect of *Clec11a* deficiency on the frequency of these cell populations ([Figure 3---figure supplement 1C--G](#fig3s1){ref-type="fig"}), their rate of BrdU incorporation ([Figure 3---figure supplement 1I--M](#fig3s1){ref-type="fig"}), or the percentage of cells that stained positively for activated caspase 3/7 (data not shown). Clec11a is therefore not required in vivo for the maintenance, survival, or the proliferation of bone marrow mesenchymal progenitors.

To functionally assess this conclusion, we cultured at clonal density enzymatically dissociated femur bone marrow cells from *Clec11a^-/-^* and sex-matched littermate control mice at 2 and 10 months of age. We observed no difference in the frequency of cells that formed CFU-F colonies or in the number of cells per colony ([Figure 2---figure supplement 1T and U](#fig2s1){ref-type="fig"}). Clec11a is therefore not required for the maintenance of CFU-F in vivo or for their proliferation in culture.

To test whether Clec11a is required for the differentiation of mesenchymal progenitors, we cultured CFU-F from *Clec11a^-/-^* and littermate control bone marrow at clonal density, then replated equal numbers of *Clec11a^-/-^* or control cells into osteogenic, adipogenic, or chondrogenic culture conditions. Consistent with the decreased osteogenesis in vivo, bone marrow stromal cells from *Clec11a^-/-^* mice gave rise to significantly fewer cells with alkaline phosphatase (a marker of mature osteoblasts and pre-adipocytes) or alizarin red (a marker of mineralization by mature osteoblasts) staining as compared to control cells under osteogenic culture conditions ([Figure 3A--D](#fig3){ref-type="fig"}). qRT-PCR analysis of cells in these cultures showed that *Clec11a* deficiency did not significantly affect the expression of *Sp7 (Osterix)*, *Runx2*, or *Col1a1* but did significantly reduce the expression of Integrin binding sialoprotein (*Ibsp*) and Dentin matrix protein 1 (*Dmp1*) ([Figure 3---figure supplement 1N](#fig3s1){ref-type="fig"}). *Sp7*, *Runx2*, and *Col1a1* are broadly expressed by immature osteogenic progenitors and osteoblasts ([@bib25]; [@bib33]; [@bib50]) whereas *Ibsp* and *Dmp1* mark mature osteoblasts ([@bib26]). Clec11a was thus required for the differentiation of bone marrow mesenchymal progenitors into mature osteoblasts.10.7554/eLife.18782.008Figure 3.Clec11a is necessary for osteogenic differentiation.(**A--D**) Osteogenic differentiation in culture of bone marrow stromal cells from the femur bone marrow of *Clec11^-/-^* mice and sex-matched littermate controls. Alkaline phosphatase staining and alizarin red staining were performed after seven days (**A** and **B**) and 14 days (**C** and **D**) to quantify osteoblast differentiation and mineralization (n = 3 independent experiments). (**E** and **F**) Adipogenic differentiation in culture of bone marrow stromal cells from the femur bone marrow of *Clec11^-/-^* mice and sex-matched littermate controls. Oil red O staining was performed after four days (n = 3 independent experiments). (**G** and **H**) Chondrogenic differentiation in cell pellets of bone marrow stromal cells from the femur bone marrow of *Clec11^-/-^* mice and sex-matched littermate controls. Toluidine blue staining was performed on cryosectioned cell pellets after 21 days (n = 3 independent experiments). (**I--K**) Representative perilipin and osteopontin (OPN) staining in femur sections of two month-old *Clec11^-/-^* mice and sex-matched littermate controls (**I** and **J**) as well as the number of adipocytes per mm^2^ in sections through the bone marrow metaphysis (**K**) (n = 3 mice per genotype, total, from three independent experiments). (**L--N**) Representative Safranin O/fast green staining in femur sections of two month-old *Clec11a^-/-^* mice and sex-matched littermate controls (**L** and **M**) as well as the number of chondrocytes per mm^2^ in sections through the growth plate (**N**) (n = 3 mice per genotype from three independent experiments). The statistical significance of differences among genotypes was assessed using two-tailed Student's t tests. All data represent mean ± SD (\*\*p\<0.01, \*\*\*p\<0.001) from female mice. The source data are in [Figure 3---source data 1](#SD3-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.008](10.7554/eLife.18782.008)10.7554/eLife.18782.009Figure 3---source data 1.Data for [Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"} and [2](#fig3s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.009](10.7554/eLife.18782.009)10.7554/eLife.18782.010Figure 3---figure supplement 1.Analysis of osteoprogenitor populations and in vivo transplantation of bone marrow stromal cells.(**A**) Gating strategy for analysis of osteoprogenitor populations from dissociated bone marrow. (**B--G**) Frequency analysis of different osteogenic progenitors in the growth plate region of 10 month-old *Clec11a^-/-^* mice and sex-matched control littermates (n = 5 mice per genotype, total, from three independent experiments). (**H--M**) Cell cycle analysis of different osteogenic progenitors in the growth plate region of 10 month-old *Clec11a^-/-^* mice and sex-matched control littermates after 14 days of BrdU labeling (n = 5 mice per genotype, total, from three independent experiments). (**N**) qPCR analysis in osteogenic differentiation cultures of BMSCs from *Clec11a^-/-^* mice and control littermates (n = 3 mice per genotype, total, from three independent experiments). (**O**) Representative perilipin and osteopontin (OPN) staining in ossicle sections. Bone marrow stromal cells from *Clec11^-/-^* mice and sex-matched littermate controls (**I** and **J**) were subcutaneously transplanted into NSG mice with collagen sponges (n = 3 mice per genotype, total, from three independent experiments). The bone ossicles were dissected eight weeks after transplantation for cryosection and immunostaining. (**P** and **Q**) Quantification of the percentage of total area that contained bone (**P**) and the number of adipocytes per mm^2^ in ossicles (**Q**; n = 3 independent experiments). The statistical significance of differences was assessed using two-tailed Student's t tests. Data represent mean ± SD: \*p\<0.05, \*\*p\<0.01. All mice were female in these experiments. The source data are in [Figure 3---source data 1](#SD3-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.010](10.7554/eLife.18782.010)10.7554/eLife.18782.011Figure 3---figure supplement 2.Analysis of the number of adipocytes and chondrocytes in 10 month-old *Clec11a^-/-^* and control femur sections.(**A--C**) Representative perilipin and osteopontin (OPN) staining in femur sections from 10 month-old *Clec11^-/-^* mice and sex-matched littermate controls (**A** and **B**) as well as the number of adipocytes per mm^2^ in sections through the bone marrow metaphysis (**C**) (n = 5 mice per genotype, total, from three independent experiments). (**D--F**) Representative Safranin O/fast green staining in femur sections from 10 month-old *Clec11a^-/-^* mice and sex-matched littermate controls (**D** and **E**) as well as the number of chondrocytes per mm^2^ in sections through the growth plate (**F**) (n = 5 mice per genotype, total, from three independent experiments). The statistical significance of differences was assessed using two-tailed Student's t tests. Data represent mean ± SD (\*\*\*p\<0.001). All mice were female in these experiments. The source data are in [Figure 3---source data 1](#SD3-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.011](10.7554/eLife.18782.011)

Under adipogenic ([Figure 3E and F](#fig3){ref-type="fig"}) and chondrogenic ([Figure 3G and H](#fig3){ref-type="fig"}) culture conditions we did not detect any difference between *Clec11a^-/-^* and control cells in terms of Oil Red O or Toluidine blue staining. Consistent with this, the number of Perilipin^+^ adipocytes ([Figure 3I--K](#fig3){ref-type="fig"}) and Safranin O^+^ chondrocytes ([Figure 3L--N](#fig3){ref-type="fig"}) in femur sections from two month-old mice did not differ between *Clec11a^-/-^* and sex matched littermate control mice. However, we did observe significantly more adipocytes in the femur sections from 10 month-old *Clec11a^-/-^* mice as compared to littermate controls ([Figure 3---figure supplement 2A--C](#fig3s2){ref-type="fig"}). The number of chondrocytes did not significantly differ between *Clec11a^-/-^* and littermate controls at 10 months of age ([Figure 3---figure supplement 2D--F](#fig3s2){ref-type="fig"}).

To test whether Clec11a is necessary for the differentiation of mesenchymal progenitors into mature osteoblasts in vivo, we cultured CFU-F from adult bone marrow at clonal density, then seeded equal numbers *Clec11a^-/-^* or control cells into collagen sponges and transplanted them subcutaneously into immunocompromised NSG mice ([Figure 3---figure supplement 1O](#fig3s1){ref-type="fig"}). Eight weeks after transplantation, ossicles generated from *Clec11a^-/-^* cells contained significantly less bone as compared to the ossicles generated from control cells ([Figure 3---figure supplement 1P](#fig3s1){ref-type="fig"}). In contrast, the number of adipocytes per unit area did not differ between ossicles containing *Clec11a^-/-^* as compared to control cells ([Figure 3---figure supplement 1Q](#fig3s1){ref-type="fig"}).

Clec11a is necessary for normal fracture healing {#s2-5}
------------------------------------------------

We performed mid-diaphyseal femur fractures in two month-old *Clec11a^-/-^* and sex-matched littermate controls. Two weeks later, *Clec11a^-/-^* mice had significantly less callus bone around the fracture site ([Figure 4A](#fig4){ref-type="fig"}) and significantly more callus cartilage ([Figure 4B](#fig4){ref-type="fig"}) as compared to controls, suggesting delayed endochondral ossification. MicroCT analysis of the callus at the fracture site two weeks after the fracture revealed significantly reduced trabecular bone volume, trabecular number, trabecular thickness, and trabecular connectivity density ([Figure 4C--H](#fig4){ref-type="fig"}) and significantly increased trabecular spacing ([Figure 4I](#fig4){ref-type="fig"}) in *Clec11a^-/-^* bones. The bone mineral density in the callus did not significantly differ between *Clec11a^-/-^* and control mice ([Figure 4J](#fig4){ref-type="fig"}). The callus volume, diameter, and polar moment of inertia were significantly increased in *Clec11a^-/-^* mice as compared to littermate controls ([Figure 4K--M](#fig4){ref-type="fig"}), further suggesting that fracture healing was compromised in *Clec11a^-/-^* mice ([@bib52]).10.7554/eLife.18782.012Figure 4.Clec11a is necessary for bone regeneration and fracture healing.(**A** and **B**) Hematoxylin and eosin (**A**; dark blue = bone marrow cells; pink = bone) and Safranin O (**B**; red = cartilage) staining of the callus around the fracture site two weeks after bone fracture. **F**, fibrous tissue. BM, bone marrow. **C**, cartilage. (**C** and **D**) Representative microCT snapshot images of the callus (**C**) and cut-plane images around the fracture site (**D**) two weeks after bone fracture. (**E--M**) MicroCT analysis of trabecular bone volume/total volume (**E**), trabecular number (**F**), trabecular thickness (**G**), connectivity density (**H**), trabecular spacing (**I**), bone mineral density (**J**), callus volume (**K**), callus diameter (**L**) and polar moment of inertia (**M**) in the callus two weeks after bone fracture (n = 3 mice per genotype, total, from three independent experiments). The statistical significance of differences was assessed using two-tailed Student's t tests. All data represent mean ± SD (\*p\<0.05, \*\*p\<0.01) from male mice that were two months old at the time of fracture. The source data are in [Figure 4---source data 1](#SD4-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.012](10.7554/eLife.18782.012)10.7554/eLife.18782.013Figure 4---source data 1.Data for [Figure 4](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.013](10.7554/eLife.18782.013)

Clec11a promotes mesenchymal progenitor differentiation into mature osteoblasts {#s2-6}
-------------------------------------------------------------------------------

To test whether Clec11a is sufficient to promote osteogenesis we constructed a HEK293 cell line that stably expressed mouse Clec11a with a C-terminal Flag tag. We affinity purified recombinant Clec11a (rClec11a) from the culture medium using anti-Flag M2 beads. Wild-type bone marrow cells were cultured to form CFU-F, then replated and grown under osteogenic culture conditions. Addition of rClec11a to these cultures significantly increased alizarin red staining, suggesting increased mineralization ([Figure 5A and B](#fig5){ref-type="fig"}). Addition of rClec11a also rescued osteogenesis by *Clec11a^-/-^* bone marrow stromal cells at 7 and 14 days after induction of differentiation ([Figure 5---figure supplement 1J--M](#fig5s1){ref-type="fig"}). Transient expression of mouse *Clec11a* cDNA in the MC3T3-E1 mouse pre-osteoblast cell line ([@bib68]) increased osteogenic differentiation by these cells in culture ([Figure 5---figure supplement 1H and I](#fig5s1){ref-type="fig"}).

To test whether Clec11a is sufficient to promote the differentiation of bone marrow mesenchymal progenitors into mature osteoblasts, we sorted LepR^+^CD105^+^CD45^-^Ter119^-^CD31^-^ cells from wild-type mice into recombinant Clecl11a (rClec11a)-containing and control cultures at clonal density. Addition of rClec11a to these cultures did not significantly affect the percentage of cells that formed CFU-F or the number of cells per colony ([Figure 5---figure supplement 1A and B](#fig5s1){ref-type="fig"}). Upon induction of differentiation, rClec11a significantly increased the number of alkaline phosphatase positive osteoblasts per colony ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). This appeared to reflect a promotion of differentiation as rClec11a did not significantly affect the frequencies of dividing osteoblasts ([Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}) or osteoblasts undergoing apoptosis within the colonies ([Figure 5---figure supplement 1F](#fig5s1){ref-type="fig"}). Consistent with the experiments above, addition of rClec11a did not significantly affect *Sp7*, *Runx2*, or *Col1a1* expression by cells within these cultures, but it did significantly increase the expression of *Ibsp* and *Dmp1* ([Figure 5---figure supplement 1G](#fig5s1){ref-type="fig"}). Clec11a is thus sufficient to promote the differentiation of bone marrow mesenchymal progenitors into mature osteoblasts.

To test whether rClec11a promotes osteogenesis in vivo, we administered daily subcutaneous injections of rClec11a to two month-old wild-type mice for 28 days. Consistent with the in vitro data, rClec11a dose-dependently increased trabecular bone volume in the distal femur metaphysis ([Figure 5C and D](#fig5){ref-type="fig"}). The higher doses of rClec11a also significantly increased trabecular number and reduced trabecular spacing ([Figure 5E--G](#fig5){ref-type="fig"}). The increased osteogenesis was associated with a significantly increased mineralized bone surface ([Figure 5H](#fig5){ref-type="fig"}) and bone formation rate ([Figure 5I](#fig5){ref-type="fig"}), but did not affect bone resorption ([Figure 5J](#fig5){ref-type="fig"}). Cortical bone parameters in the femur diaphysis were not affected by rClec11a in these experiments ([Figure 5---figure supplement 1N--S](#fig5s1){ref-type="fig"}). rClec11a thus promotes osteogenesis in wild-type mice in vivo.10.7554/eLife.18782.014Figure 5.Recombinant Clec11a promotes osteogenesis in vitro and in vivo.(**A** and **B**) Osteogenic differentiation of stromal cells from femur bone marrow of wild-type mice. Vehicle or 10 ng/ml rClec11a were added to osteogenic culture conditions and alizarin red staining was assessed 14 days later to test whether Clec11a would promote osteogenesis (n = 3 independent experiments with duplicate cultures per treatment per experiment). (**C**) Representative microCT images of trabecular bone in the distal femur metaphysis of wild-type female mice treated with daily subcutaneous doses of rClec11a for 28 days (panels **C--G** reflect n = 6 mice per treatment, total, from six independent experiments). (**D--G**) MicroCT analysis of trabecular bone parameters from the distal femur metaphysis of mice treated with daily subcutaneous doses of rClec11a for 28 days. (**H** and **I**) Mineralized surface/bone surface ratio (**H**) and bone formation rate (**I**) in trabecular bone in the femur metaphysis of mice treated with rClec11a for 28 days (n = 3 mice per genotype, total, from three independent experiments). (**J**) Bone resorption analysis based on the deoxypyridinoline/creatinine ratio in the urine (n = 4 mice per genotype, total, from four independent experiments). (**K**) Representative microCT images of trabecular bone in the distal femur metaphysis of control mice treated with vehicle, or *Clec11a^-/-^* mice treated with vehicle or 50 µg/kg daily subcutaneous injections of rClec11a for 28 days (panels **K--Q** reflect n = 4--6 mice per treatment, total, from four independent experiments). (**L--Q**) Trabecular bone parameters from the distal femur metaphysis of mice in the experiment shown in panel **J**. The statistical significance of differences among treatments was assessed using one-way ANOVAs with Tukey's multiple comparison tests. All data represent mean ± SD (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001) from female mice that were two months (**C--J**) or six months (**K--Q**) old at the start of the experiment. The source data are in [Figure 5---source data 1](#SD5-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.014](10.7554/eLife.18782.014)10.7554/eLife.18782.015Figure 5---source data 1.Data for [Figure 5](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.015](10.7554/eLife.18782.015)10.7554/eLife.18782.016Figure 5---figure supplement 1.Effects of rClec11a on osteogenic differentiation and cortical bone analysis in mice wild-type mice treated with rClec11a.(**A** and **B**) Percentage of sorted LepR^+^CD105^+^CD45^-^Ter119^-^CD31^-^ femur bone marrow cells that formed CFU-F (**A**) and the total number of cells per colony (**B**) when cultured with or without 10 ng/ml rClec11a for eight days (n = 5 independent experiments). (**C** and **D**) Clonal osteogenic differentiation of sorted LepR^+^CD105^+^CD45^-^Ter119^-^CD31^-^ femur bone marrow cells in the presence or absence of 10 ng/ml rClec11a. The percentage of colonies that contained osteoblasts (**C**) and the total number of osteoblasts per colony (**D**) based on alkaline phosphatase staining (n = 5 independent experiments). (**E** and **F**) rClec11a did not affect the proliferation or survival of osteoblasts in culture. EdU was added into the medium to quantify the proliferation of osteoblasts for eight days. Caspase-3/7 activity was detected on day eight of differentiation to quantify the frequency of apoptotic osteoblasts (n = 5 independent experiments). (**G**) qPCR analysis of osteogenic markers (n = 4 independent experiments). (**H** and **I**) MC3T3-E1 cells expressing empty vector or mouse *Clec11a* cDNA were subjected to osteogenic differentiation for 14 days (n = 3 independent experiments with duplicate cultures per treatment per experiment). The statistical significance of differences in panels **A--I** was assessed using two-tailed Student's t tests. (**J--M**) Osteogenic differentiation in culture of stromal cells from *Clec11^-/-^* or littermate control femur bone marrow, with or without rClec11a. Alkaline phosphatase staining and alizarin red staining were performed after seven days (**J** and **K**) or 14 days (**L** and **M**) to quantify osteoblast differentiation and mineralization (n = 3 independent experiments). (**N**) Representative microCT images of cortical bone in the femur diaphysis of two month-old wild-type female mice injected with vehicle or various doses of rClec11a. (**O--S**) MicroCT analysis of the total area (**O**), cortical area (**P**), cortical area/total area (**Q**), cortical thickness (**R**) and cortical bone mineral density (**S**) in the femur diaphysis (n = 6 mice per genotype, total, from six independent experiments). The statistical significance of differences was assessed using one-way ANOVAs with Tukey's multiple comparison tests. Data represent mean ± SD (\*\*p\<0.01, \*\*p\<0.001). All mice were female in these experiments. The source data are in [Figure 5---source data 1](#SD5-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.016](10.7554/eLife.18782.016)

To test whether administration of rClec11a can rescue the bone loss phenotype in *Clec11a^-/-^* mice, we administered daily subcutaneous injections of 50 µg/kg rClec11a to six month-old *Clec11a^-/-^* mice for 28 days. This restored plasma Clec11a to control levels (data not shown). Consistent with this, *Clec11a^-/-^* mice exhibited significantly increased trabecular bone volume ([Figure 5K and L](#fig5){ref-type="fig"}), trabecular number, trabecular thickness, connectivity density, and decreased trabecular spacing ([Figure 5M--Q](#fig5){ref-type="fig"}). After rClec11a administration to *Clec11a^-/-^* mice, trabecular bone parameters were similar to those in normal control mice.

rClec11a administration prevents osteoporosis {#s2-7}
---------------------------------------------

Ovariectomy in adult mice induces osteoporosis by increasing bone resorption ([@bib63]). We ovariectomized mice at two months of age then administered daily subcutaneous injections of recombinant human parathyroid hormone (PTH) fragment 1--34, rClec11a, or vehicle for 28 days before analysis by microCT. MicroCT analysis showed that trabecular bone volume and number were significantly reduced in ovariectomized mice ([Figure 6A--C](#fig6){ref-type="fig"}) while trabecular spacing was significantly increased ([Figure 6E](#fig6){ref-type="fig"}). Daily administration of PTH to ovariectomized mice significantly increased trabecular bone volume ([Figure 6B](#fig6){ref-type="fig"}) and trabecular number ([Figure 6C](#fig6){ref-type="fig"}), while reducing trabecular spacing ([Figure 6E](#fig6){ref-type="fig"}). Ovariectomy did not significantly affect the plasma Clec11a level (data not shown). Daily administration of rClec11a to ovariectomized mice significantly increased trabecular bone volume ([Figure 6B](#fig6){ref-type="fig"}) and trabecular number ([Figure 6C](#fig6){ref-type="fig"}), while reducing trabecular spacing ([Figure 6E](#fig6){ref-type="fig"}). Cortical bone parameters were not significantly changed by PTH or Clec11a administration in these experiments ([Figure 6---figure supplement 1A--F](#fig6s1){ref-type="fig"}). rClec11a can therefore prevent the loss of trabecular bone in ovariectomized mice.10.7554/eLife.18782.017Figure 6.Recombinant Clec11a prevents osteoporosis.(**A**) Representative microCT images of trabecular bone in the distal femur metaphysis. Two month-old sham operated (Mock) or ovariectomized (OVX) female mice received daily subcutaneous injections with vehicle, 40 µg/kg human PTH, or 50 µg/kg rClec11a for 28 days. (**B--E**) MicroCT analysis of trabecular bone parameters in the distal femur metaphysis of the mice from the experiment in panel **A** (n = 6--8 mice per treatment, total, from six independent experiments). (**F**) Bone resorption analysis based on the deoxypyridinoline/creatinine ratio in the urine (n = 4 mice per treatment, total, from four independent experiments). (**G**) Trabecular bone formation rate based on calcium double labeling in the distal femur metaphysis (n = 3--4 mice per treatment, total, from at least three independent experiments). (**H**) Representative microCT images of trabecular bone in the distal femur metaphysis. Two month-old wild-type female mice were treated with daily intraperitoneal injections of PBS or 20 mg/kg dexamethasone (DEX) for 28 days, with or without daily subcutaneous injections of vehicle, 40 µg/kg human PTH, or 50 µg/kg rClec11a. (**I--L**) Trabecular bone parameters of mice from the same experiments (panels **I--N** reflect n = 4 mice per treatment, total, from four independent experiments). (**M**) Trabecular bone formation rate based on calcium double labeling in the distal femur metaphysis (n = 3--4 mice per treatment, total, from at least three independent experiments). (**N**) Bone resorption analysis based on the deoxypyridinoline/creatinine ratio in the urine (n = 4 mice per treatment, total, from four independent experiments). The statistical significance of differences was assessed using one-way ANOVAs with Tukey's multiple comparisons tests. All data represent mean ± SD (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001) from female mice that were two months old at the start of the experiment. The source data are in [Figure 6---source data 1](#SD6-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.017](10.7554/eLife.18782.017)10.7554/eLife.18782.018Figure 6---source data 1.Data for [Figure 6](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.018](10.7554/eLife.18782.018)10.7554/eLife.18782.019Figure 6---figure supplement 1.Cortical bone analysis in ovariectomized mice.(**A**) Representative microCT images of cortical bone in the femur diaphysis. Two month-old sham operated (Mock) or ovariectomized (OVX) female mice were injected with vehicle, 40 µg/kg human PTH (1--34) or 50 µg/kg rClec11a for 28 days. (**B--F**) MicroCT analysis of the total area (**B**), cortical area (**C**), cortical area/total area (**D**), cortical thickness (**E**) and cortical bone mineral density (**F**) in the femur diaphysis (n = 6--8 mice per genotype, total, from six independent experiments). (**G** and **H**) Histomorphometry analysis of osteoclast number/bone surface and osteoblast number/bone surface in trabecular bone from the distal femur metaphysis (n = 4 mice per genotype, total, from four independent experiments). The statistical significance of differences was assessed using one-way ANOVAs with Tukey's multiple comparison tests. Data represent mean ± SD (\*\*p\<0.01, \*\*\*p\<0.001). All mice were female in these experiments. The source data are in [Figure 6---source data 1](#SD6-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.019](10.7554/eLife.18782.019)10.7554/eLife.18782.020Figure 6---figure supplement 2.Hematopoietic and cortical bone analysis in dexamethasone-injected mice.(**A--D**) White blood cell (**A**), neutrophil (**B**), lymphocyte (**C**) and monocyte (**D**) counts in two month-old wild-type female mice treated with daily intraperitoneal injections of PBS or 20 mg/kg dexamethasone (DEX) for 28 days, with or without daily subcutaneous injections of vehicle, 40 µg/kg human PTH, or 50 µg/kg rClec11a (n = 4 mice per genotype, total, from four independent experiments). (**E**) Representative microCT images of cortical bone in the femur diaphysis of the same mice. (**F--J**) MicroCT analysis of the total area (**B**), cortical area (**C**), cortical area/total area (**D**), cortical thickness (**E**) and cortical bone mineral density (**F**) in the femur diaphysis of the mice in this experiment (panels **F--M**, n = 4 mice per genotype, total, from four independent experiments). (**K**) Plasma Clec11a level measurement by ELISA. (**L** and **M**) Histomorphometry analysis of osteoclast number/bone surface and osteoblast number/bone surface in trabecular bone from the distal femur metaphysis. The statistical significance of differences among treatments was assessed using one-way ANOVAs with Tukey's multiple comparison tests. Data represent mean ± SD: \*\*p\<0.01, \*\*\*p\<0.001. Data represent mean ± SD (\*\*p\<0.01, \*\*\*p\<0.001). All mice were female in these experiments. The source data are in in [Figure 6---source data 1](#SD6-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.020](10.7554/eLife.18782.020)

Consistent with the fact that ovariectomy increases bone resorption ([@bib17]), the urinary bone resorption marker deoxypyridinoline was significantly increased in ovariectomized mice as compared to sham operated controls ([Figure 6F](#fig6){ref-type="fig"}). Administration of rClec11a or PTH did not significantly affect deoxypyridinoline levels ([Figure 6F](#fig6){ref-type="fig"}) or numbers of osteoclasts ([Figure 6---figure supplement 1G](#fig6s1){ref-type="fig"}) in ovariectomized mice. However, based on calcein double labeling and histomorphometry analysis, the trabecular bone formation rate ([Figure 6G](#fig6){ref-type="fig"}) and the number of osteoblasts associated with trabecular bones ([Figure 6---figure supplement 1H](#fig6s1){ref-type="fig"}) were significantly increased by rClec11a or PTH administration. rClec11a thus prevented the loss of trabecular bone in ovariectomized mice by promoting bone formation.

We also assessed the effect of rClec11a on a model of secondary osteoporosis in which bone loss was induced by dexamethasone injection, mimicking glucocorticoid-induced osteoporosis in humans ([@bib41]; [@bib69]). Daily intraperitoneal administration of 20 mg/kg dexamethasone for four weeks in mice significantly reduced lymphocyte numbers in the blood without significantly affecting neutrophil or monocyte counts ([Figure 6---figure supplement 2A--D](#fig6s2){ref-type="fig"}). MicroCT analysis of the distal femur metaphysis showed significantly reduced trabecular bone volume and thickness in the dexamethasone-treated as compared to vehicle-treated mice ([Figure 6H--L](#fig6){ref-type="fig"}). Treatment of dexamethasone-treated mice with PTH significantly increased trabecular bone volume, trabecular number, and trabecular thickness while significantly reducing trabecular spacing ([Figure 6H--L](#fig6){ref-type="fig"}). Dexamethasone treatment did not significantly affect plasma Clec11a levels ([Figure 6---figure supplement 2K](#fig6s2){ref-type="fig"}), but administration of rClec11a to dexamethasone-treated mice significantly increased trabecular bone volume and trabecular number while significantly reducing trabecular spacing ([Figure 6H--L](#fig6){ref-type="fig"}). Dexamethasone treatment also significantly reduced cortical thickness but neither PTH nor rClec11a rescued this effect in these experiments ([Figure 6---figure supplement 2E--J](#fig6s2){ref-type="fig"}).

Consistent with the fact that dexamethasone reduces bone formation ([@bib17]), the rate of trabecular bone formation based on calcein double labeling ([Figure 6M](#fig6){ref-type="fig"}) and the numbers of osteoblasts in trabecular bone ([Figure 6---figure supplement 2L](#fig6s2){ref-type="fig"}) were significantly reduced in dexamethasone-treated as compared to vehicle-treated mice. Administration of PTH or rClec11a significantly increased the trabecular bone formation rate ([Figure 6M](#fig6){ref-type="fig"}) and the number of osteoblasts ([Figure 6---figure supplement 2L](#fig6s2){ref-type="fig"}) in dexamethasone-treated mice. As expected, dexamethasone treatment, or administration of PTH or rClec11a, did not significantly affect deoxypyridinoline levels ([Figure 6N](#fig6){ref-type="fig"}) or osteoclast numbers ([Figure 6---figure supplement 2M](#fig6s2){ref-type="fig"}). rClec11a thus prevented the loss of trabecular bone in dexamethasone-treated mice by promoting bone formation.

rClec11a administration reverses osteoporosis {#s2-8}
---------------------------------------------

To test whether rClec11a could reverse bone loss after the onset of osteoporosis we ovariectomized two month-old wild-type mice and waited for four weeks before administering PTH or rClec11a daily for another four weeks. MicroCT analysis showed that trabecular and cortical bone volumes as well as trabecular number were significantly reduced in ovariectomized mice ([Figure 7A--C](#fig7){ref-type="fig"}, and [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). Trabecular spacing was significantly increased in ovariectomized mice ([Figure 7E](#fig7){ref-type="fig"}). Daily administration of PTH to ovariectomized mice increased trabecular bone volume ([Figure 7B](#fig7){ref-type="fig"}) and significantly reduced trabecular spacing relative to untreated ovariectomized mice ([Figure 7E](#fig7){ref-type="fig"}). PTH treatment also significantly increased cortical area ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}) and cortical thickness ([Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). Daily administration of rClec11a to ovariectomized mice significantly increased trabecular bone volume ([Figure 7B](#fig7){ref-type="fig"}) and trabecular number ([Figure 7C](#fig7){ref-type="fig"}), while reducing trabecular spacing ([Figure 7E](#fig7){ref-type="fig"}) relative to untreated ovariectomized mice. rClec11a did not significantly affect cortical area ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}) or cortical thickness ([Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}) in ovariectomized mice. rClec11a can thus reverse trabecular bone loss after the onset of ovariectomy-induced osteoporosis.10.7554/eLife.18782.021Figure 7.Recombinant Clec11a reverses osteoporosis and promotes osteogenesis by human bone marrow stromal cells.(**A**) Representative microCT images of trabecular bone in the distal femur metaphysis. Two month-old sham operated (Mock) or ovariectomized (OVX) female mice were left untreated for 28 days for osteoporosis to develop, and then received daily subcutaneous injections with vehicle, 40 µg/kg human PTH, or 50 µg/kg rClec11a for another 28 days. (**B--G**) MicroCT analysis of trabecular bone parameters in the distal femur metaphysis of the mice from the experiment in panel **A** (panels **B--G** reflect n = 4 mice per treatment, total, from four independent experiments). The statistical significance of differences among treatments was assessed using one-way ANOVAs with Tukey's multiple comparisons tests. All data represent mean ± SD (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001) from female mice that were two months old at the start of the experiment. (**H--K**) Osteogenic differentiation in culture of hMSCs. Alkaline phosphatase staining and alizarin red staining were performed after eight days (**H** and **I**) and 21 days (**J** and **K**) to quantify osteoblast differentiation and mineralization (n = 6 independent experiments). (**L--O**) Ossicle formation by human bone marrow stromal cells in NSG mice. Vehicle or 50 µg/kg rhClec11a was subcutaneously injected daily for 4 (**L** and **M**) or 8 (**N** and **O**) weeks before the ossicles were dissected and sectioned for H and E staining (n = 5--9 ossicles per treatment, total, from two independent experiments). F, fibrous tissue. HA, HA/TCP carrier. The statistical significance of differences in **H--O** was assessed using two-tailed Student's t tests. Data represent mean ± SD (\*p\<0.05 \*\*p\<0.01, \*\*\*p\<0.001). The source data are in [Figure 7---source data 1](#SD7-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.021](10.7554/eLife.18782.021)10.7554/eLife.18782.022Figure 7---source data 1.Data for [Figure 7](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.022](10.7554/eLife.18782.022)10.7554/eLife.18782.023Figure 7---figure supplement 1.Cortical bone analysis in ovariectomized mice.(**A**) Representative microCT images of cortical bone in the femur diaphysis. Two month-old sham operated (Mock) or ovariectomized (OVX) female mice were left untreated for 28 days, and then injected daily with vehicle, 40 µg/kg human PTH (1--34) or 50 µg/kg rClec11a for another 28 days. (**B--F**) MicroCT analysis of the total area (**B**), cortical area (**C**), cortical area/total area (**D**), cortical thickness (**E**) and cortical bone mineral density (**F**) in the femur diaphysis (n = 4 mice per genotype, total, from four independent experiments). The statistical significance of differences among treatments was assessed using one-way ANOVAs with Tukey's multiple comparison tests. Data represent mean ± SD (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001). All mice were female in these experiments. The source data are in [Figure 7---source data 1](#SD7-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18782.023](10.7554/eLife.18782.023)

Recombinant human Clec11a promotes osteogenesis {#s2-9}
-----------------------------------------------

To test whether human Clec11a also promotes osteogenesis, we constructed a HEK293 cell line that stably expressed human Clec11a with a C-terminal Flag tag, then affinity purified recombinant human Clec11a (rhClec11a) from the culture medium. Addition of rhClec11a to human bone marrow stromal cells cultured under osteogenic culture conditions significantly increased osteoblast differentiation based on alkaline phosphatase ([Figure 7H and I](#fig7){ref-type="fig"}) and alizarin red staining ([Figure 7J and K](#fig7){ref-type="fig"}).

To test whether rhClec11a promotes osteogenesis by human bone marrow stromal cells in vivo we subcutaneously transplanted a suspension of human bone marrow stromal cells, hydroxyapatite/tricalcium phosphate particles, and fibrin gel into immunocompromised NSG mice ([@bib5]) and administered daily subcutaneous injections of rhClec11a or vehicle for 4 or 8 weeks. rhClec11a significantly accelerated bone formation in the ossicles after four weeks and significantly increased bone formation in the ossicles after eight weeks ([Figure 7L--O](#fig7){ref-type="fig"}). rhClec11a thus promotes osteogenesis by human bone marrow stromal cells in vivo.

Discussion {#s3}
==========

We have identified a new osteogenic factor, Clec11a, which maintains the adult skeleton by promoting the osteogenesis. Clec11a was necessary and sufficient to promote osteogenesis in culture and in vivo. *Clec11a* deficiency significantly reduced bone volume in both limb bones and vertebrae of adult mice ([Figure 2](#fig2){ref-type="fig"}). Clec11a was expressed by subsets of bone marrow stromal cells, osteoblasts, osteocytes, and hypertrophic chondrocytes, particularly in the metaphysis, but also in portions of cortical bone ([Figure 1](#fig1){ref-type="fig"}). In light of the unanticipated osteogenic activity of Clec11a, and its role in the maintenance of the adult skeleton, we propose to call this growth factor Osteolectin, a name that is more descriptive of both biological function and protein structure.

Clec11a/Osteolectin appears to promote bone formation by promoting the differentiation of mesenchymal progenitors into mature osteoblasts. *Clec11a/Osteolectin* deficient bone marrow stromal cells formed significantly fewer osteoblasts and mineralized bone matrix in culture ([Figure 3A--D](#fig3){ref-type="fig"}) with significantly lower expression of the mature osteoblast markers *Ibsp* and *Dmp1* ([Figure 3---figure supplement 1N](#fig3s1){ref-type="fig"}). Addition of recombinant Clec11a/Osteolectin to cultures of wild-type bone marrow stromal cells significantly increased the formation of osteoblasts ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}) as well as *Ibsp* and *Dmp1* expression ([Figure 5---figure supplement 1G](#fig5s1){ref-type="fig"}). Clec11a/Osteolectin deficient bone marrow stromal cells also formed less bone in the ossicles in vivo ([Figure 3---figure supplement 1O--Q](#fig3s1){ref-type="fig"}). Recombinant Clec11a/Osteolectin promoted bone formation in the ossicles in vivo ([Figure 7L--O](#fig7){ref-type="fig"}). In contrast to its effects on osteogenic differentiation, *Clec11a/Osteolectin* deficiency did not affect the frequency, proliferation, or survival of bone marrow mesenchymal progenitors in vivo ([Figure 3---figure supplement 1B--M](#fig3s1){ref-type="fig"}). Recombinant Clec11a/Osteolectin also did not have any effect on the frequency of CFU-F that formed colonies in culture ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) or the number of cells per colony ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). We conclude that Clec11a/Osteolectin promotes the osteogenic differentiation of mesenchymal progenitors but not their proliferation or survival.

Hypertrophic chondrocytes can also transdifferentiate into osteoblasts and osteocytes during endochondral ossification ([@bib57]; [@bib73]; [@bib76]). Thus, in addition to promoting the differentiation of mesenchymal progenitors into mature osteoblasts, Clec11a/Osteolectin might also promote the transdifferentiation of hypertrophic chondrocytes into osteoblasts. Lineage tracing studies will be required in future to test this.

Nobody has yet identified the receptor for Clec11a/Osteolectin, limiting our ability to study the signaling mechanisms by which it promotes osteogenesis. We do observe binding of flag-tagged Clec11a/Osteolectin to the surface of osteogenic cell lines (data not shown). We hypothesize that Clec11a/Osteolectin promotes the osteogenic differentiation of mesenchymal progenitors by binding to a signaling receptor on the surface of these cells. Identification of this receptor will require significant additional work beyond the scope of the current study.

Phylogenic analysis showed that Clec11a/Osteolectin is most closely related to Clec3b/Tetranectin. *Tetranectin* expression increases during mineralization by osteogenic progenitors in culture and overexpression of *Tetranectin* in PC12 cells increases the bone content of tumors formed by these cells ([@bib70]). Tetranectin deficient mice exhibit kyphosis as a result of asymmetric growth plate development in vertebrae ([@bib22]); however, it is unknown whether Tetranectin is required for osteogenesis in vivo. Tetranectin is found in both cartilaginous fish and bony fish but Clec11a/Osteolectin is only found in bony fish and higher vertebrate species. This suggests that Clec11a/Osteolectin evolved in bony species to promote osteogenic differentiation and mineralization. Among mammals Clec11a/Osteolectin is highly conserved: human and mouse Clec11a/Osteolectin proteins are 85% identical and 90% similar. Consistent with this, recombinant human Clec11a/Osteolectin promoted osteogenesis by human bone marrow stromal cells in culture and in vivo ([Figure 7H--O](#fig7){ref-type="fig"}).

Materials and methods {#s4}
=====================

Mice and cell lines {#s4-1}
-------------------

To generate *Clec11a^-/-^* mice, *Cas9* mRNA and *sgRNAs* were transcribed using mMESSAGE mMACHINE T7 Ultra Kit and MEGAshortscript Kit (Ambion), purified by MEGAclear Kit (Ambion), and microinjected into C57BL/6 zygotes by the Transgenic Core Facility of the University of Texas Southwestern Medical Center (UTSW). Chimeric mice were genotyped by restriction fragment length polymorphism (RFLP) analysis and backcrossed onto a C57BL/Ka background to obtain germline transmission. Mutant mice were backcrossed onto a C57BL/Ka background for 3 to 6 generations prior to analysis. Wild-type C57BL/Ka mice were used for rClec11a injection, ovariectomy, and dexamethasone injection experiments. All procedures were approved by the UTSW Institutional Animal Care and Use Committee (Animal protocol number: 2016--101334-G). The cell lines used in this study included HEK293 and MC3T3-E1 (Subclone 4), which were obtained from ATCC and authenticated by STR profiling. They were shown to be free of mycoplasma contamination.

Flow cytometry {#s4-2}
--------------

Antibodies used to analyze hematopoietic stem cells (HSCs) and multipotent hematopoietic progenitors (MPPs) included anti-CD150-PE-Cy5 (BioLegend, clone TC15-12F12.2, 1:200), anti-CD48-FITC (eBioscience, clone HM48-1, 1:200), anti-Sca-1-PEcy7 (eBioscience, E13-161.7, 1:200), anti-c-Kit-APC-eFluor780 (eBioscience, clone 2B8, 1:200) and the following antibodies against lineage markers: anti-Ter119-PE (eBioscience, clone TER-119, 1:200), anti-B220-PE (BioLegend, clone 6B2, 1:400), anti-Gr-1-PE (BioLegend, clone 8C5, 1:800), anti-CD2-PE (eBioscience, clone RM2-5, 1:200), anti-CD3-PE (BioLegend, clone 17A2, 1:200), anti-CD5-PE (BioLegend, clone 53--7.3, 1:400) and anti-CD8-PE (eBioscience, clone 53--6.7, 1:400). The following antibodies were used to identify restricted hematopoietic progenitors: anti-CD34-FITC (eBioscience, clone RAM34, 1:100); anti-CD16/32 Alexa Fluor 700 (eBioscience, clone 93, 1:200); anti-CD135-PEcy5 (eBioscience, clone A2F10, 1:100); anti-CD127-Biotin (BioLegend, clone A7R34, 1:200) + Streptavidin-PE-CF592 (BD Biosciences, 1:500); anti-cKit-APC-eFluor780 (eBioscience, clone 2B8, 1:200); anti-ScaI-PEcy7 (eBioscience, clone E13-161.7, 1:200) and lineage markers listed above. The following antibodies were used to identify differentiated cells: anti-CD71-FITC (BD Biosciences, clone C2, 1:200); anti-Ter119-APC (eBioscience, clone TER-119, 1:200); anti-CD3-PE (BioLegend, clone 17A2, 1:200); anti-B220-PEcy5 (eBioscience, clone RA3-6B2, 1:400); anti-Mac-1-APC-eFluor780 (eBioscience, M1/70, 1:200) and anti-Gr-1-PEcy7 (BioLegend, clone RB6-8C5, 1:400). Anti-CD45.2-FITC (BioLegend, clone 104, 1:200) and anti-CD45.1-APC-eFluor-78 (eBioscience, clone A20, 1:100) were used to distinguish donor from recipient cells in competitive reconstitution assays. The following antibodies were used to distinguish subpopulations of bone marrow stromal cells: anti-CD45-APC (eBioscience, clone 30-F11, 1:200), anti-Ter119-APC (eBioscience, clone TER-119, 1:200), anti-CD31-APC (Biolegend, clone MEC13.3, 1:200), anti-Tie2-APC (BioLegend, clone TEK4, 1:200), anti-Thy1.1-FITC (eBioscience, clone HIS51, 1:200), anti-Thy1.2-FITC (eBioscience, clone 30-H12, 1:200), anti-CD51-biotin (BioLegend, clone RMV-7, 1:100), anti-CD51-PE (BioLegend, clone RMV-7, 1:100), anti-Ly-51-PEcy7 (BioLegend, clone 6C3, 1:200), anti-CD200-PE (BioLegend, clone OX-90, 1:200), anti-CD105-Pacific Blue (BioLegend, clone MJ7/18), anti-LepR-biotin antibody (R and D systems, BAF497, 1:100) and anti-PDGFRα-biotin (eBioscience, clone APA5, 1:200). Cells were stained with antibodies in 200 µl of staining medium (HBSS + 2% fetal bovine serum) on ice for 1 hr, and then washed by adding 2 ml of staining buffer followed by centrifugation. Biotin-conjugated antibodies were incubated with streptavidin-PE or streptavidin-Brilliant Violet 421 (Biolegend, 1:500) for another 20 min (Biolegend, 1:500). Cells were resuspended in staining medium with 1 µg/ml DAPI (Invitrogen) and analyzed with a FACSCanto flow cytometer (BD Biosciences) or sorted using a FACSAria flow cytometer (BD Biosciences) with a 130 µm nozzle. To assess proliferation in vivo, mice were given a single intraperitoneal injection of BrdU (100 mg/kg body mass) and maintained on 0.5 mg/ml BrdU in the drinking water for 14 days. The frequency of BrdU^+^ SSCs was then analyzed by flow cytometry using the APC BrdU Flow Kit (BD Biosciences).

Bone marrow digestion and CFU-F culture {#s4-3}
---------------------------------------

Enzymatic digestion of bone marrow cells and CFU-F cultures were performed as described previously ([@bib66]). Briefly, intact marrow plugs were flushed from the long bones and subjected to two rounds of enzymatic digestion at 37°C for 15 min each. The digestion buffer contained 3 mg/ml type I collagenase (Worthington), 4 mg/ml dispase (Roche Diagnostic) and 1 U/ml DNase I (Sigma) in HBSS with calcium and magnesium. The cells were resuspended in staining medium (HBSS + 2% fetal bovine serum) with 2 mM EDTA to stop the digestion. To form CFU-F colonies, freshly dissociated single-cell suspensions were plated at clonal density in 6-well plates (5 × 10^5^ cells/well) or 10 cm plates (5 × 10^6^ cells/dish) with DMEM (Gibco) plus 20% fetal bovine serum (Sigma F2442, lot 14M255, selected to support CFU-F growth), 10 µM ROCK inhibitor (Y-27632, TOCRIS), and 1% penicillin/streptomycin (Invitrogen). Cultures were maintained at 37°C in gas-tight chambers (Billups-Rothenberg, Del Mar, CA) that were flushed daily for 30 s with 5% O~2~ and 5% CO~2~ (balance Nitrogen) to maintain a low oxygen environment that promoted survival and proliferation ([@bib47]). The CFU-F culture medium was changed on the second day after plating to wash out contaminating macrophages, then changed every 3--4 days after that. CFU-F colonies were counted eight days after plating by staining with 0.1% Toluidine blue in 4% formalin solution.

In vitro differentiation {#s4-4}
------------------------

Osteogenic and adipogenic differentiation were assessed by replating primary CFU-F cells into 48-well plates (25,000 cells/cm^2^). On the second day of culture, the medium was replaced with adipogenic (four days) or osteogenic (seven days or 14 days) medium (StemPro MSC differentiation kits; Life Technologies). Equal numbers of cells from wild-type and *Clec11a^-/-^* cultures were replated so there was no difference in the density of cells of different genotypes. In some experiments, clonal differentiation potential was assessed by sorting 500 bone marrow LepR^+^CD105^+^CD45^-^Ter119^-^CD31^-^ cells into each well of a 6-well plate to form CFU-F colonies at clonal density over an eight day period. Then the culture medium was replaced with osteogenic differentiation medium. Seven to 14 days later, the percentage of colonies that contained osteoblasts and the numbers of osteoblasts per colony were quantified by StemTAG Alkaline Phosphatase Staining and Activity Assay Kit (Cell Biolabs) and alizarin red staining (Sigma).

Chondrogenic potential was assessed by centrifuging 2 × 10^5^ CFU-F cells to form cell pellets, which were then cultured in chondrogenic medium for 21 days (StemPro chondrogenesis differentiation kit; Life Technologies), changing the culture medium every 2--3 days. Chondrocyte formation within the cell pellets was assessed by cryosectioning and Toluidine blue staining ([@bib62]). The osteogenic differentiation of human bone marrow stromal cells and MC3T3-E1 cells was tested using the StemPro osteogenesis differentiation kit (Life Technologies). Images were acquired using an Olympus IX81 microscope.

MicroCT analysis {#s4-5}
----------------

Femurs and lumbar vertebrae were dissected, fixed overnight in 4% paraformaldehyde and stored in 70% ethanol at 4°C. Femurs and lumbar vertebrae were scanned at an isotropic voxel size of 3.5 µm and 7 µm, respectively, with peak tube voltage of 55 kV and current of 0.145 mA (µCT 35; Scanco Medical AG, Bassersdorf, Switzerland). A three-dimensional Gaussian filter (σ = 0.8) with a limited, finite filter support of one was used to suppress noise in the images, and a threshold of 263--1000 was used to segment mineralized bone from air and soft tissues. Trabecular bone parameters were measured in the distal metaphysis of the femurs. The region of interest was selected from below the distal growth plate where the epiphyseal cap structure completely disappeared and continued for 100 slices toward the proximal end of the femur. Contours were drawn manually a few voxels away from the endocortical surface to define trabecular bones in the metaphysis ([@bib8]). Cortical bone parameters were measured by analyzing 100 slices in mid-diaphysis femurs. Vertebral bone parameters were measured by analyzing 200 slices in the middle of L3 lumbar vertebrae. The fracture callus was scanned at an isotropic voxel size of 6 µm with the same settings as described above. The region of interested was selected from 200 slices above the fracture site to 200 slices below the fracture site (400 slices in total), including the entire callus. A segmentation threshold of 263--500 was used to analyze the trabecular parameters in the fracture callus.

Long-term competitive reconstitution assays in irradiated mice {#s4-6}
--------------------------------------------------------------

Two month-old adult recipient mice were irradiated with an XRAD 320 irradiator (Precision X-Ray Inc.), giving two doses of 550 rad, delivered at least 2 hr apart. C57BL/Ka-Thy-1.1 (CD45.2) donor mice and C57BL/Ka-Thy-1.2(CD45.1) recipient mice were used in transplant experiments. 300,000 donor whole bone marrow cells from *Clec11a^-/-^* or littermate control mice (CD45.2) were transplanted along with 300,000 recipient whole bone marrow cells (CD45.1) into lethally irradiated recipient mice (C57BL/Ka-Thy-1.1 x C57BL/Ka-Thy-1.2 (CD45.1/CD45.2) heterozygotes). Peripheral blood was obtained from the tail veins of recipient mice at 4 to 16 weeks after transplantation. Blood was subjected to ammonium-chloride lysis of the red blood cells and leukocytes were stained with antibodies against CD45.1, CD45.2, B220, Mac-1, CD3 and Gr-1 to assess hematopoietic chimerism by donor and recipient cells by flow cytometry.

Bone sectioning and immunostaining {#s4-7}
----------------------------------

Dissected bones were fixed in 4% paraformaldehyde overnight, decalcified in 10% EDTA for four days, and dehydrated in 30% sucrose for two days. Bones were sectioned (10 µm) using the CryoJane tape-transfer system (Leica). Sections were blocked in PBS with 10% horse serum for 30 min and then stained overnight at 4°C with goat IgG control (R and D Systems, 1:500), goat anti-Clec11a antibody (R and D systems, 1:500), rabbit anti-Aggrecan antibody (Chemicon, 1:500), rabbit anti-Perilipin antibody (Sigma, 1:2000) or goat anti-Osteopontin antibody (R and D, 1:500). Donkey anti-goat Alexa Fluor 488, Donkey anti-goat Alexa Fluor 647 and donkey anti-rabbit Alexia Fluor 555 were used as secondary antibodies (Invitrogen, 1:500). Slides were mounted with anti-fade prolong gold with DAPI (Invitrogen). Images were acquired using a Zeiss LSM780 confocal microscope or Olympus IX81 microscope.

Calcein double labeling and histomorphometry analysis {#s4-8}
-----------------------------------------------------

On day 0 and day 7, mice were injected intraperitoneally with 10 mg/kg body mass calcein dissolved in calcein buffer (0.15 M NaCl plus 2% NaHCO~3~ in water) and sacrificed on day 9. The tibias were fixed overnight in 4% paraformaldehyde at 4°C, dehydrated in 30% sucrose for two days and sectioned without decalcification (7 µm sections). Mineral apposition and bone formation rates were determined as previously described ([@bib14]). For the quantification of osteoblast number/bone surface and osteoclast number/bone surface, decalcified 10 µm femur sections were stained histochemically for alkaline phosphatase (Roche) or tartrate-resistant acid phosphatase (Sigma) activity. Growth plate chondrocytes were identified based on staining with Safranin O/fast green (American MasterTech) and quantified using Image J. Alizarin red/alcian blue double staining was performed as described previously ([@bib59]).

Bone fractures {#s4-9}
--------------

A stainless steel wire was inserted into the intramedullary canal of the femur through the knee after anesthesia, and a bone fracture was introduced in the femur mid-diaphysis by 3-point bending. Buprenorphine was injected every 12 hr up to 72 hr after the surgery.

Bone resorption analysis {#s4-10}
------------------------

Bone resorption rate was determined by measuring urinary levels of deoxypyridinoline (DPD) using a MicroVue DPD ELISA Kit (Quidel). The DPD values were normalized to urinary creatinine levels using the MicroVue Creatinine Assay Kit (Quidel).

Recombinant protein purification {#s4-11}
--------------------------------

Mouse Clec11a cDNA was cloned into pcDNA3 vector (Invitrogen) containing a C-terminal 1XFlag-tag, which was then transfected into HEK293 cells with Lipofectamine 2000 (Invitrogen) and subjected to stable cell line selection using 1 mg/ml G418 (Sigma). Stable clones with high Clec11a expression were cultured in DMEM plus 10% FBS (Sigma), and 1% penicillin/streptomycin (Invitrogen). Culture medium was collected every two days, centrifuged to eliminate cellular debris, and stored with 1 mM phenylmethylsulfonyl fluoride at 4°C to inhibit protease activity. One litter of culture medium was filtered through a 0.2 µm membrane to eliminate cellular debris (Nalgene) before being loaded onto a chromatography column containing 2 ml Anti-FLAG M2 Affinity Gel (Sigma), with a flow rate of 1 ml/min. The column was sequentially washed using 20 ml of high salt buffer (20 mM Tris-HCl, 300 mM KCl, 10% Glycerol, 0.2 mM EDTA) followed by 20 ml of low salt buffer (20 mM Tris-HCl, 150 mM KCl, 10% Glycerol, 0.2 mM EDTA) and finally 20 ml of PBS. The FLAG-tagged Clec11a was then eluted from the column using 10 ml 3X FLAG peptide (100 μg/ml) in PBS or protein storage buffer (50 mM HEPES, 150 mM NaCl and 10% glycerol, pH = 7.5). Eluted protein was concentrated using Amicon Ultra-15 Centrifugal Filter Units (Ultracel-10K, Millipore), then quantitated by SDS-PAGE and colloidal blue staining (Invitrogen) and stored at −80°C. The recombinant human Clec11a was generated and purified in the same way.

Osteoporosis models {#s4-12}
-------------------

For ovariectomy-induced osteoporosis, 8 week-old virgin female mice were anesthetized using Isoflurane, shaved, and disinfected with Betadine. A dorsal midline incision was made and the periovarian fat pad was gently grasped to exteriorize the ovary. The fallopian tube was then clamped off and the ovary was removed by cutting above the clamped area. The uterine horn was returned into the abdomen and the same process was repeated on the other side. After surgery, buprenorphine was given for analgesia, and mice were closely monitored until they resumed full activity. Vehicle, 40 µg/kg PTH (1--34) or 50 µg/kg rClec11a were subcutaneously injected daily starting one day or four weeks after the surgery and continuing for 28 days then the mice were analyzed. For dexamethasone-induced osteoporosis, PBS or 20 mg/kg dexamethasone was injected peritoneally into eight week-old virgin female mice daily for 28 days. Vehicle, 40 µg/kg PTH (1--34) or 50 µg/kg rClec11a were subcutaneously injected at the same time.

In vivo transplantation of bone marrow stromal cells {#s4-13}
----------------------------------------------------

Mouse and human bone marrow stromal cell ossicle formation in vivo was assessed as described previously ([@bib5]). Briefly, 2 × 10^6^ mouse primary CFU-F cells were seeded into collagen sponges (Gelfoam, Pfizer), incubated at 37°C for 90 min, with or without 10 ng/ml rClec11a, and then transplanted subcutaneously into NSG mice. The ossicles formed by these cells were analyzed eight weeks after transplantation by cryosectioning and immunostaining with antibodies against perilipin and osteopontin. For human bone marrow stromal cells, 2 × 10^6^ cells were incubated with 40 mg of hydroxyapatite (HA)/tricalcium phosphate (TCP) particles (65%/35%, Zimmer Dental, Warsaw IN), with or without 10 ng/ml rhClec11a, and rotated for 2 hr at 37°C. The cell/carrier slurry was centrifuged at 135xg for 5 min and embedded in a fibrin gel by adding 15 µl of human fibrinogen (3.2 mg/ml in sterile PBS) with 15 µl of human thrombin (25 U/ml in sterile 2% CaCl~2~ in PBS). The gels were left at room temperature for 10 min to clot, then transplanted subcutaneously into NSG mice. The ossicles formed by these cells were analyzed 4 or 8 weeks after transplantation by cryosectioning and H and E staining. Some of the mice were treated with daily subcutaneous injections of 50 µg/kg human recombinant Clec11a.

qPCR {#s4-14}
----

For quantitative reverse transcription PCR (qPCR), 6000 PDGFRα^+^CD45^-^Ter119^-^CD31^-^ cells were flow cytometrically sorted from enzymatically dissociated bone marrow into Trizol (Invitrogen). RNA was extracted and reverse transcribed into cDNA using SuperScript III (Invitrogen). qPCR was performed using a Roche LightCycler 480. The primers used for qPCR analysis included *Clec11a (NM_009131.3)*: 5'-AGG TCC TGG GAG GGA GTG-3' and 5'-GGG CCT CCT GGA GAT TCT T-3'; *Runx2 (NM_001146038.2)*: 5'- TTA CCT ACA CCC CGC CAG TC-3' and 5'-TGC TGG TCT GGA AGG GTC C-3'; *Sp7 (NM_130458.3)*: 5'- ATG GCG TCC TCT CTG CTT GA-3' and 5'-GAA GGG TGG GTA GTC ATT TG-3'; *Ibsp (NM_008318.3)*: 5'-AGT TAG CGG CAC TCC AAC TG-3' and 5'-TCG CTT TCC TTC ACT TTT GG-3'; *Dmp1* (NM_016779.2): 5'-TGG GAG CCA GAG AGG GTA G-3' and 5'- TTG TGG TAT CTG GCA ACT GG-3'; *Actb (NM_007393.5)*: 5'-GCT CTT TTC CAG CCT TCC TT-3' (Forward) and 5'-CTT CTG CAT CCT GTC AGC AA-3' (Reverse).

EdU incorporation and caspase-3/7 activity {#s4-15}
------------------------------------------

EdU was added into osteogenic differentiation medium at day 0 (10 μM final concentration) and maintained for the duration of the differentiation phase of the culture (8 days). The cultures were fixed by adding 1% paraformaldehyde on ice for 5 min then stained with alkaline phosphatase substrates (NBT/BCIP, Roche). Cells were then incubated with PBS supplemented with 3% FCS and 0.1% saponin for 5 min at room temperature, followed by Click-iT Plus reaction cocktail (Life Technologies) incubated for 30 min with 5 μM Alexa Fluor 555-azide. Cells were washed with PBS supplemented with 3% FCS and 0.1% saponin twice and quantified using an Olympus IX81 microscope. Caspase-3/7 enzymatic activity within individual cells growing adherently in culture plates was measured by adding CellEvent Caspase-3/7 Green Detection Reagent (a substrate for activated caspase-3/7, 2 μM final concentration; Life Technologies) to the differentiation medium at the end of the experiment and incubated for 30 min before fixation, alkaline phosphatase staining, and quantification.

Blood cell counts {#s4-16}
-----------------

Peripheral blood was collected from the tail vein using Microvette CB 300 K2E tubes (Sarstedt) and counted using a HEMAVET HV950 cell counter (Drew Scientific).

Hematopoietic colony formation {#s4-17}
------------------------------

Hematopoietic colony formation was assessed by seeding 20,000 unfractionated mouse femur bone marrow cells into MethoCult M3334 or MethoCult M3234 supplemented with 10 ng/ml GM-CSF (STEMCELL Technologies). The cultures were incubated at 37°C for 10 days and then colonies were counted under the microscope.

ELISA measurement of plasma Clec11a level {#s4-18}
-----------------------------------------

Mouse plasma was diluted 1:1 using 2x PBS buffer and 100 μl of diluted serum was coated on each well of the 96-well ELISA plate (COSTAR 96-WELL EIA/RIA STRIPWELL PLATE) at 4°C for 16 hr. The plate was then washed three times with washing buffer (PBS with 0.1% Tween-20), blocked with 300 μl ELISA Blocker Blocking Buffer (Thermo, N502) for 2 hr at room temperature, and washed for three times with washing buffer. Anti-Clec11a antibody (1 μg/ml diluted in 100 μl of PBS buffer with 0.1% Tween-20 per well) was then added and incubated at room temperature for 2 hr, washed three times with washing buffer, followed by HRP-conjugated donkey anti-Goat IgG secondary antibody (0.8 μg/ml diluted in 100 μl of PBS buffer with 0.1% Tween-20 per well) incubation at room temperature for 1 hr. After washing for three times, 100 μl of SureBlue TMB Microwell Peroxidase Substrate was added to each well and incubated at room temperature in the dark for 15 min. Finally, 100 μl of the TMB stop solution was added into each well and the optical density was measured at 450 nm.

Biomechanical analysis {#s4-19}
----------------------

To assess biomechanical properties, the right femurs were harvested from mice, wrapped in saline-soaked gauze, and stored at --20°C. The femurs were rehydrated in PBS for at least 3 hr before testing, and then kept in a humidified chamber and preconditioned with 20 cycles of bending displacement (0.1 mm). Without immersion, the femurs were loaded to fracture with three-point bending (each holding point was 4 mm from the middle break point) under displacement control (3 mm/min) using a material testing system (Instron model \# 5565, Norwood, MA).

Genotyping {#s4-20}
----------

To genotype *Clec11a^+/+^, Clec11^+/-^*, and *Clec11a^-/-^* mice the following primers were used: 5'-TTT GGG TGC TGG GAA GCC C-3' and 5'-TTG CAC TGA GTC GCG GGT G-3' (*Clec11a^+/+^*: 910 bp; *Clec11^+/-^* or *Clec11a^-/-^*: 538 bp). To distinguish between *Clec11a^+/-^*and *Clec11a^-/-^* mice, the following primers were used: 5'-GAG GAA GAG GAA ATC ACC ACA GC-3' and 5'-TTG CAC TGA GTC GCG GGT G-3' (*Clec11a^+/-^*: 482 bp; *Clec11a^-/-^*: no amplification product).

Statistical analysis {#s4-21}
--------------------

The statistical significance of differences between the two treatments was assessed using two-tailed Student\'s t tests. The statistical significance of differences among more than two groups was assessed using one-way ANOVAs with Tukey's multiple comparison tests. The statistical significance of differences in long-term competitive reconstitution assays was assessed using two-way ANOVAs with Sidak's multiple comparison tests. All data represent mean ± SD. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Clec11a is an osteogenic factor that promotes the maintenance of the adult skeleton\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Ophir D Klein (Reviewer \#1), and the evaluation has been overseen by Janet Rossant as the Senior Editor and Reviewing Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this elegant and well-executed manuscript, the Morrison lab reports on their exciting discovery that a C-type lectin domain protein, Clec11a, promotes osteogenesis. Clec11a maintains the adult skeleton by promoting osteogenic differentiation of mesenchymal progenitors. The authors first determined that Clec11a is highly expressed in skeletal lineage cells by gene and protein expression analyses. They then employed the CRISPR-Cas9 system to generate a Clec11a knock out mouse to test if Clec11a is necessary for hematopoiesis and osteogenesis in vivo. They found that Clec11a deficiency led to weaker bones under conditions of normal homeostasis and also after fracture healing. The authors also tested whether administration of recombinant Clec11a is sufficient to prevent and reverse osteoporosis using micro-CT and histomorphometric analyses. The identification of Clec11a as a novel agonist of bone maintenance and fracture healing is of high interest and the data presented are very compelling. While the study does not define a clear molecular mechanism of action for Clec11a, multiple models of osteoporosis were used to demonstrate the efficacy of rClec11a, greatly strengthening the clinical relevance of the study.

Major revisions required:

Although there was overall support for the findings, there were concerns from the reviewers about the robustness of the data on the bone phenotypes, specifically about the rigor of the µCT and histomorphometry data. Reviewer 1 noted that there are standard protocols for assessing and reporting mouse bone microstructure (for example: Bouxsein et al., 2010 JBMR. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography). As presented here, the explanations for the exact location of the volume of interest and the method used to define trabecular and cortical bone regions are vague. If indeed the same number of slices were chosen for every timepoint, then it is likely that different anatomical regions within the growing femur were assessed. Details regarding image processing, including the algorithm used for image filtration and the approach used for calibration and image segmentation, should be added. Many of the units used by the authors to describe the various bone features differ from those recommended in standard protocols.

In addition, there was concern as to whether the sample size of mice analyzed was sufficient to support the conclusions in all cases. Typically, unless the effect size is substantial, labs need to study 8 to 10 mice/genotype/sex/treatment group for most bone parameters. Because you present \"representative\" images in this paper and no clear indication of the number or sex of animals included in each group, the reviewers were not convinced that all the reported in vivo effects represent true positive results. It will be important for you to address these concerns as far as is possible within the two month time frame, or focus your results on those experiments where you have a fully powered cohort.

Other concerns include explaining why mice with similar ages and genotypes have very different bone measures (e.g., BV/TV) in different figures and a need for a better description of the recombinant protein you produced and administered. Downstream experiments (beyond the scope of the present paper) could then determine if the effect on bone cells is direct or indirect, why fracture healing is delayed (osteoblast recruitment or transdifferentiation failure), and whether recombinant CLEC11A can be used as a therapeutic for common skeletal diseases such as fractures and osteoporosis.

Overall there was enthusiasm for the finding of a potentially novel osteogenic factor.
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Author response

*\[...\] Major revisions required:*

*Although there was overall support for the findings, there were concerns from the reviewers about the robustness of the data on the bone phenotypes, specifically about the rigor of the µCT and histomorphometry data. Reviewer 1 noted that there are standard protocols for assessing and reporting mouse bone microstructure (for example: Bouxsein et al., 2010 JBMR. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography). As presented here, the explanations for the exact location of the volume of interest and the method used to define trabecular and cortical bone regions are vague. If indeed the same number of slices were chosen for every timepoint, then it is likely that different anatomical regions within the growing femur were assessed. Details regarding image processing, including the algorithm used for image filtration and the approach used for calibration and image segmentation, should be added.*

We believe we followed the standard protocols described by Bouxsein et al. (see details below). We have updated the text of the manuscript to clarify more precisely the locations of the volume measurements. We have included more details regarding the number of slices that were analyzed. Bone growth was very limited in the adult mice analyzed in our study so we do not believe that any of our results are confounded by changes in anatomical regions caused by bone growth. We have also updated the text to include more details regarding image processing and analysis.

For the femur trabecular bones, we started analyzing slices at the bottom of the distal growth plate, where the epiphyseal cap structure completely disappeared, and continued for 100 slices (3.5 μm/slice) toward the proximal end of the femur. Contours were drawn manually a few voxels away from the endocortical surface to define trabecular bones in the metaphysis, as suggested by the guideline ([Figure 4D](#fig4){ref-type="fig"}; JBMR 25:1468). For the femur cortical bones, 100 slices (3.5 μm/slice) in the mid-diaphysis were analyzed. The same anatomical regions were analyzed for all the samples throughout the manuscript. We have added details of microCT measurements and analyses as requested.

*Many of the units used by the authors to describe the various bone features differ from those recommended in standard protocols.*

In the original manuscript we used ratios instead of "%" for Bone volume/Total volume and Cortical area/Total area (i.e. 0.05 rather than 5%). We used "per mm" instead of "1/mm" (as recommended by Bouxsein et al.) for trabecular number and a few other measurements. We have now changed the units to be identical to those recommended by Bousein et al., though these changes have no effect on the data or the conclusions.

*In addition, there was concern as to whether the sample size of mice analyzed was sufficient to support the conclusions in all cases. Typically, unless the effect size is substantial, labs need to study 8 to 10 mice/genotype/sex/treatment group for most bone parameters. Because you present \"representative\" images in this paper and no clear indication of the number or sex of animals included in each group, the reviewers were not convinced that all the reported* in vivo *effects represent true positive results. It will be important for you to address these concerns as far as is possible within the two month time frame, or focus your results on those experiments where you have a fully powered cohort.*

There are multiple issues that bear clarification here:

1\) In the original manuscript, we specified the number of mice per genotype and the number of independent experiments for each figure panel in the figure legends.

2\) Although we did not have n=8 mice/sex/genotype in all experiments, all of our conclusions were based on statistically significant differences in which the statistical tests took into account variability within treatments as well as numbers of replicates. Many of the effects reported in our manuscript were large effects. For example, Clec11a deficiency has a large negative effect on bone volume in vivo (e.g. [Figure 2D](#fig2){ref-type="fig"}) and bone formation in culture (e.g. [Figure 3D](#fig3){ref-type="fig"}). Treatment with recombinant Clec11a has large positive effects on bone formation in culture (e.g. [Figure 5B](#fig5){ref-type="fig"}) and bone formation in vivo (e.g. [Figure 5K](#fig5){ref-type="fig"}). The fact that we consistently observed statistically significant differences in many different kinds of experiments, with both gain and loss of function assays that showed opposite results, in vitro and in vivo, makes it exceedingly unlikely that the effects could have been observed by chance.

3\) The representative images in the figures were usually accompanied by bar graphs that showed all of the data from all of the experiments (with numbers of replicates and experiments in the figure legend) as well as statistical analysis.

Most of our experiments require more than 2 months to perform. However, we have performed new experiments and added more replicates for in vivo administration of rClec11a in wild-type mice (new [Figure 5C--G](#fig5){ref-type="fig"}), and for prevention of ovariectomy-induced osteoporosis by rClec11a (new [Figure 6A--E](#fig6){ref-type="fig"}). The new data were consistent with the old data: in vivo administration of rClec11a promotes bone formation in wild-type mice and in ovariectomized mice.

*Other concerns include explaining why mice with similar ages and genotypes have very different bone measures (e.g., BV/TV) in different figures and a need for a better description of the recombinant protein you produced and administered.*

Thank you for calling our attention to this. We have revised our presentation of these data to avoid confusion. We used both males and females of each genotype in [Figure 2](#fig2){ref-type="fig"}, whereas only females were used in [Figures 5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} (e.g. ovariectomy studies could only be performed on females). Since adult male mice have significantly higher BV/TV values than female mice (see [Figure 3B](#fig3){ref-type="fig"}; JBMR 22:1197), it is not surprising that the 2 month-old BV/TV value in the control mice of [Figure 2](#fig2){ref-type="fig"} (around 10%) is higher than in the rest of the manuscript (4-8%). Thus, the differences in BV/TV values in different figures mainly reflect expected biological differences, not experimental error. We have revised the manuscript to make clear the sexes that were used in each experiment. We have also added more detailed information on the recombinant protein and how it was purified.
